When was Antibodies.com founded?

Antibodies.com was founded in 2015 and raised its 1st funding round 4 years after it was founded.

Where is Antibodies.com located?

Antibodies.com is headquartered in Cambridge, United Kingdom.

Which legal entities is Antibodies.com associated with?

Antibodies.com is associated with ANTIBODIES.COM LIMITED.

How many employees does Antibodies.com have?

As of Oct 31, 2026, the latest employee count at Antibodies.com is 7.

Is Antibodies.com a funded company?

Antibodies.com is a funded company, having raised a total of $***** in its 1st and only funding round, a Seed round on Jul 02, 2019.

When was the latest funding round of Antibodies.com?

Antibodies.com's latest funding was a $***** Seed round on Jul 02, 2019, with participation from 1 investor.

Where does Antibodies.com rank among its competitors?

Antibodies.com ranks 9th amongst 280 active competitors, of which 16 are funded. It stands 8th in terms of total funding among its competitors. The most recent competitor to raise funding was Pixelgen Technolgies, which secured $15.5M in Aug, 2026.

Who are the top competitors of Antibodies.com?

Antibodies.com's top competitors include Sino Biological, GenScript and Pixelgen Technolgies. Among them, Pixelgen Technolgies secured the most recent funding round in August, 2026.

Antibodies.com - 2026 Company Profile, Team, Funding, Competitors & Financials

Antibodies.com is a seed company based in Cambridge (United Kingdom), founded in 2015 by Stewart Newlove and Mark Humphreys. It operates as a Provider of portfolio of diagnostic reagents. Antibodies.com has raised $506K in funding from Nidobirds Venture. The company has 280 active competitors, including 16 funded and 39 that have exited. Its top competitors include companies like Sino Biological, GenScript and Pixelgen Technolgies.

Company Details

Antiboides.com provides a portfolio of diagnostic reagents. The company develops a range of proteins, immunoassay kits, peptides, antibodies and more for research and diagnostic purposes. The flagship products are primary antibodies, secondary antibodies like Anti- IgG Antibody, Biotinylated Anti-Human IgG and more. They also proteins & peptide molecule reagents like TNF a Human, IL4 a Human, and also gives different ELISA testing kits based on their testing samples. They can filter the search by choosing their clonality, reactivity, applications and more.

Website: antibodies.com
Social
Email ID: *****@antibodies.com
Phone Number: +44 **********

Key Metrics

Founded Year

2015

Location

Cambridge, United Kingdom

Stage

Seed

Total Funding

$506K in 1 round

Latest Funding Round

Seed, Jul 02, 2019, $*****

Investors

Nidobirds Venture & 9 more

Ranked

9^th among 280 active competitors

Employee Count

7 as on Oct 31, 2026

Similar Companies

Sino Biological & 334 more

View Antibodies.com's full profile

Antibodies.com is associated with 1 legal entity given below:

Legal Entity Name	Date of Incorporation	Revenue	Latest Employee Count	Reports
ANTIBODIES.COM LIMITED CIN: 09563058 , United Kingdom, Active	Apr 26, 2015	-	3 (As on Apr 30, 2021)

Antibodies.com has raised a total funding of $506K over 1 round. Its latest funding round was a Seed round on Jul 02, 2019 for $*****. 1 investor participated in its latest round. Antibodies.com has 2 institutional investors and 8 angel investors.

Here is the list of recent funding rounds of Antibodies.com:

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Jul 02, 2019	7247242	Seed	1392063	9973027	7166392	5029215

Access funding benchmarks and valuations. Sign up today!

View details of Antibodies.com's funding rounds and investors

The founders of Antibodies.com are Stewart Newlove and Mark Humphreys.

Here are the details of Antibodies.com's key team members:

Stewart Newlove: Founder of Antibodies.com.
Contact Info: 1 email address
Mark Humphreys: Co-Founder and Director of Antibodies.com.

View details of Antibodies.com's Founder profiles and Board Members

Antibodies.com's employee count trend

Antibodies.com has 7 employees as of Oct 26. Here is Antibodies.com's employee count trend over the years:

Uncover Antibodies.com's growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Antibodies.com include Sino Biological, GenScript and Pixelgen Technolgies. Here is the list of Top 10 competitors of Antibodies.com, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Sino Biological 2007, Beijing (China), Series A	Provider of reagents,and kits for clinical research	$29.4M	Qiming Venture Partners, CTS Capital & 1 others	63/100
2nd	GenScript 2002, Piscataway (United States), Public	Provider of reagents and instruments for life sciences research	$15M	Kleiner Perkins, Vermögensclub & 1 others	55/100
3rd	Pixelgen Technolgies 2020, Stockholm (Sweden), Series B	Developer of ground-breaking technologies for biomedical research and diagnostics	$21.5M	Flat Capital, Industrifonden & 2 others	55/100
4th	Shanghai OPM Biosciences 2013, Pudong (China), Series B	Antibody culture media and vaccine culture products developer	$14.4M	CPE, China Life Great Health Fund & 5 others	54/100
5th	Mabtech 1986, Nacka (Sweden), Acquired	Develops antibodies and ELISA kits	-	Merieux Equity Partners, IK Partners & 1 others	53/100
6th	ITBMed 2016, Stockholm (Sweden), Series A	Developer of monoclonal antibodies to prevent transplant rejections	$87M	3E Bioventures Capital, Yonjin Capital & 2 others	51/100
7th	Immuno-Biological Laboratories 1982, Fujioka (Japan), Public	Manufacture antibodies	-	Japan Asia Investment, Hokkaido Venture Capital ... & 3 others	49/100
8th	GeneTex 1997, Hsinchu (Taiwan), Early Stage	GeneTex is a manufacturer and supplier of bioreagents for life science research.	$4.3M	-	49/100
9th	Antibodies.com 2015, Cambridge (United Kingdom), Seed	Provider of portfolio of diagnostic reagents	$506K	Nidobirds Venture, Torianna Consultants & 8 others	46/100
10th	Allele Biotech 1999, San Diego (United States), Series B	cGMP iPSCs and cell therapy CDMO accelerating regenerative medicine programs	$18M	NIH, HHS & 1 others	48/100